Mubadala Investment Company, a global investment firm based in Abu Dhabi, has partnered with CBC Group, Asia’s largest healthcare-focused asset management group, to acquire 100% of UCB Pharma’s mature business in China. This acquisition encompasses UCB’s neurology and allergy portfolios, alongside its Zhuhai manufacturing site. The deal, expected to close in Q4 2024, follows conditions such as antitrust clearance. For 2023, the combined net sales of these medicines in China were 131 million euros. This investment aligns with Mubadala’s strategy to expand its Asian footprint, particularly through healthcare-focused transactions. Key executives from both entities have expressed their strategic commitment to improving healthcare access in China through this transaction.
Healthcare, Investment Management, Biopharmaceuticals,China, United Arab Emirates, Belgium
https://www.zawya.com/press-release/companies-news/mubadala-co-invests-in-ucbs-mature-business-in-china-to-reinforce-its-long-term-commitment-to-the-asian-market-uuicfds7